Assembly Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing HSV-2 and liver disease programs, with strong phase I data and a key partnership accelerating HSV-2 development. Upcoming milestones include a profit-share decision, phase II data for HSV-2 and hep delta, and expansion into cholestatic liver diseases.
-
The meeting covered board elections, executive compensation, auditor ratification, and amendments to incentive and stock purchase plans. All proposals passed with a quorum present, and no questions were raised by shareholders.
-
Multiple clinical programs are advancing, with key catalysts expected for HSV and hepatitis delta. ABI-6250 is expanding into PBC and PSC, with Phase II trials and data on the horizon. Financial runway extends into 2028, and partnering discussions for hepatitis B assets are ongoing.
-
The discussion highlighted progress in advancing antiviral candidates for HSV and hepatitis D, with strong early clinical data and strategic partnerships driving pipeline momentum. Oral therapies aim to address unmet needs in efficacy, convenience, and transmission, with key data readouts expected by 2027.
Fiscal Year 2025
-
Phase I-B studies of ABI-1179 and ABI-5366 in recurrent genital herpes showed impressive efficacy, with weekly dosing regimens achieving up to 98% reduction in HSV-2 shedding and strong safety profiles. Both candidates are advancing toward phase II, with further optimization and regulatory discussions planned.
-
The conference highlighted strong interim results for two potent, long-acting herpes virus therapies, with over 90% reduction in viral shedding and lesions, and detailed plans for upcoming data releases and phase 2 trials. The company is also advancing oral hepatitis delta and HBV programs, supported by a robust financial position and partnership with Gilead.
-
Four major clinical catalysts are expected in the next six months, including key data from HBV, hepatitis delta, and genital herpes programs. Large, de-risking trials are underway, with efficacy and convenience as top priorities for advancing assets. Collaboration with Gilead and a strong cash runway support ongoing development.